



The [¹⁸F]2-fluoro-1,3-thiazolyl moiety—an easily-accessible structural motif for prospective molecular imaging radiotracers

Fabrice G. Siméon*, Matthew T. Wendahl, Victor W. Pike

Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm. B3 C346A, 10 Center Drive, Bethesda, MD 20892-1003, USA

ARTICLE INFO

Article history:

Received 3 June 2010

Revised 9 September 2010

Accepted 13 September 2010

Available online 17 September 2010

Keywords:

Radiofluorination

1,3-Thiazole

Microwave-assisted synthesis

ABSTRACT

2-Fluoro-1,3-thiazoles were rapidly and efficiently labeled with no-carrier-added fluorine-18 ($t_{1/2} = 109.7$ min) by treatment of readily prepared 2-halo precursors with cyclotron-produced [¹⁸F]fluoride ion. The [¹⁸F]2-fluoro-1,3-thiazolyl moiety constitutes a new and easily-labeled structural motif for prospective molecular imaging radiotracers.

Published by Elsevier Ltd.

Interest in the efficient synthesis of new fluoro compounds as potential drugs and imaging agents is growing dramatically.¹ Fluorinated drugs include antibiotics, sedatives, antidepressants and anti-tumor agents.^{1,2} Moreover, methods for introducing fluorine-18 ($t_{1/2} = 109.7$ min) into organic molecules have become increasingly important for the development of radiotracers for positron emission tomography (PET),³ a sensitive and powerful technique for molecular imaging in animal and human subjects in vivo, and hence for clinical research and diagnosis.⁴ For the development of PET radiotracers, the preferred source of fluorine-18 is [¹⁸F]fluoride ion, obtained from the ¹⁸O(p,n)¹⁸F reaction on ¹⁸O-enriched water.⁵ This production method is very high yielding and importantly gives the [¹⁸F]fluoride ion at a very high 'no-carrier-added' (NCA) specific radioactivity. High specific radioactivity (typically >1 Ci/ μ mol) is often mandatory for the safety and efficacy of PET radiotracers.⁶

The introduction of fluoride ion or [¹⁸F]fluoride ion at an alkyl carbon is usually straightforward.⁶ Fluoroalkanes are however generally more susceptible to metabolic defluorination in vivo than fluoroarenes.⁷ Therefore, the latter are often more desirable targets in the development of drugs and of ¹⁸F-labeled imaging agents. [¹⁸F]Fluoride ion may be incorporated readily into electron-deficient benzenes⁶ and also into pyridines^{6,8} at their 2- and 4-positions by aromatic nucleophilic substitution reactions, and at all positions in electron-rich or electron-poor benzenes and pyridines by reaction with diaryliodonium salts.⁹ Fast efficient methods for utilizing [¹⁸F]fluoride ion in the fluorination of other arenes, especially other heteroarenes, have however been little explored.

1,3-Thiazole can be regarded as isosteric with benzene and pyridine.¹⁰ Replacement of a phenyl or pyridinyl group with a 1,3-thiazolyl group may therefore lead to an improved drug or receptor ligand. A striking example occurs among diarylacetylene-type metabotropic glutamate sub-type receptor 5 (mGluR5) ligands. Here pairing of a substituted 1,3-thiazolyl group with a substituted phenyl group in the diarylacetylene provides ligands with similar or higher potency than the pairing of other aryl groups.¹¹ Such 1,3-thiazoles appear susceptible to metabolism by oxidative ring opening.¹² However, one report suggests that fluorination of a 1,3-thiazolyl group might lead to better resistance to metabolism in vivo.¹³ We hypothesized that the 2-position in 1,3-thiazoles would be an attractive site for facile incorporation of fluorine-18 from [¹⁸F]fluoride ion and moreover might deliver a relatively metabolically stable [¹⁸F]2-fluoro-1,3-thiazolyl structural motif.

In order to establish reaction conditions for the preparation of [¹⁸F]2-fluorothiazoles, we first sought a simple method to prepare reference 2-fluorothiazoles. Among the few methods reported for preparing such fluoro compounds, including fluoro-de-diazotiation¹⁴ or nucleophilic substitution,^{15,16} nucleophilic substitution with fluoride ion in 2-halo-1,3-thiazoles¹⁶ appeared attractive since the precursor halo compounds were quite accessible.

2-Bromo-1,3-thiazole (**1**) was submitted to fluorination with potassium fluoride and an equimolar amount of the cryptand, Kryptofix® 2.2.2 (K 2.2.2) or the crown ether 18-crown-6, in various solvents (DMSO, MeCN or DMF) under microwave irradiation. We found that fluorination was almost quantitative after irradiation for 10 min at 150 °C (35 W) in DMSO. The conversion of 2-bromo-1,3-benzothiazole (**2**) into the corresponding 2-fluoro derivative (**8**) also proceeded in very high yield under these conditions (Table 1).

* Corresponding author.

E-mail address: simeonf@mail.nih.gov (F.G. Siméon).


Table 1
Yields of 2-fluorothiazoles produced under microwave irradiation

| | Precursor | | Fluoro-product | Yield ^a (%) |
|---|-----------|----|----------------|------------------------|
| | R | X | | |
| 1 | H | Br | 7 | 95 |
| 2 | | Br | 8 | 89 |
| 3 | | Cl | 9 | 78 |
| 4 | | Br | 9 | 72 |
| 5 | | I | 9 | 9 |
| 6 | | Br | 10 | 55 |

^a Yield for isolated and analytically pure compound.

We decided to test the generality of these microwave conditions for the rapid high-yield preparation of other 2-fluoro-thiazole derivatives. First we prepared the 2-chloro-, 2-bromo- and 2-iodo-1,3-thiazolyl compounds, **3–5**,¹⁷ as simple analogs of a potent mGluR5 ligand, namely 3-[(2-methyl-1,3-thiazol-4-yl)-ethynyl]-pyridine.¹⁸ These halo compounds were subjected to fluorination under the most effective conditions found for **2**. The target fluoro derivative **9** was successfully isolated in high yield from the chloro (**3**) and bromo (**4**) precursors (Table 1). The yield of **9** from the iodo precursor **5** was however low (Table 1).

We also prepared the 2-bromo and *N*-Me derivative (**6**) of the powerful antibiotic, thiabendazole, as a precursor for fluorination (Scheme 1). Previous work has shown that thiabendazole retains high fungicidal and bactericidal activity after 2-halogenation¹⁹ (halo = Cl or Br) of the thiazolyl group or *N*-methylation²⁰ of the imidazolyl ring. Fluorination of **6** in DMSO for 10 min with micro-

**Scheme 1.** Synthesis of *N*-methyl-2-fluoro-thiabendazole (**10**).**Table 2**
RCYs of [¹⁸F]2-fluoro-thiazoles from NCA [¹⁸F]fluoride ion

| | Precursor | | Reaction conditions | [¹⁸ F]Fluoro-product | RCY ^a |
|---|-----------|----|---------------------------|----------------------------------|------------------|
| | R | X | | | |
| 1 | H | Br | DMSO, 150 °C, 30 min | [¹⁸ F]7 | 29 |
| 1 | H | Br | DMSO, MW (130 °C, 10 min) | [¹⁸ F]7 | 81 |
| 2 | | Br | MeCN, 80 °C, 30 min | [¹⁸ F]8 | 19 |
| 2 | | Br | MeCN, 150 °C, 30 min | [¹⁸ F]8 | 19 |
| 2 | | Br | DMF, 80 °C, 30 min | [¹⁸ F]8 | 21 |
| 2 | | Br | DMF, 150 °C, 30 min | [¹⁸ F]8 | 24 |
| 2 | | Br | DMSO, 80 °C, 30 min | [¹⁸ F]8 | 26 |
| 2 | | Br | DMSO, 150 °C, 30 min | [¹⁸ F]8 | 35 |
| 2 | | Br | DMSO, MW (150 °C, 10 min) | [¹⁸ F]8 | 47 |
| 3 | | Cl | DMSO, MW (130 °C, 8 min) | [¹⁸ F]9 | 14.5 |
| 4 | | Br | DMSO, MW (130 °C, 8 min) | [¹⁸ F]9 | 14 |
| 5 | | I | DMSO, MW (130 °C, 8 min) | [¹⁸ F]9 | 2.0 |
| 4 | | Br | DMSO, MW (130 °C, 10 min) | [¹⁸ F]9 | 45 |
| 6 | | Br | DMSO, MW (130 °C, 10 min) | [¹⁸ F]10 | 23 |
| 7 | H | F | MeCN, 110 °C, 35 min | [¹⁸ F]7 | 26 |

^a Isolated decay-corrected radiochemical yield from starting [¹⁸F]fluoride ion.

wave heating at 130 °C gave *N*-methyl-2-fluorothiabendazole (**10**) in good yield (Scheme 1; Table 1).

The apparent rapidity and effectiveness of the fluorination of 2-halo-1,3-thiazoles with potassium fluoride under microwave irradiation encouraged us to explore the preparation of [¹⁸F]2-fluoro-1,3-thiazoles with cyclotron-produced NCA [¹⁸F]fluoride ion under thermal or microwave heating conditions (Table 2). We found that treatment of a low amount of the 2-fluorothiazole **7** (1.1 mg; 1.0 mmol) with [¹⁸F]fluoride ion in the presence of K⁺-K 2.2.2 in acetonitrile (500 μL) at 110 °C produced carrier-added [¹⁸F]**7** in 26% decay-corrected radiochemical yield (RCY) within 35 min (Table 2).

Similar treatment of the 2-bromo compound **1** in DMSO with NCA [¹⁸F]fluoride ion at 150 °C for 30 min gave [¹⁸F]**7** in 29% RCY (Table 2). Use of microwave heating (10 min at 40–90 W; 130 °C) dramatically increased the RCY of [¹⁸F]**7** to 81%. Similarly, under thermal heating

conditions, the RCY of [^{18}F]**8** increased with temperature between 80 and 150 °C, and with solvent polarity, among acetonitrile, DMF or DMSO. Thus, at 80 °C in DMSO, [^{18}F]**8** was obtained in only 26% RCY. A higher RCY of [^{18}F]**8** (35%) was obtained in DMSO at 150 °C for 30 min. Under inert atmosphere in DMSO with brief microwave heating (90 W, 150 °C, 10 min), [^{18}F]**8** was obtained in 47% RCY, and with a measured specific activity of 2.5 Ci/ μmol . Increase in temperature had less effect when using acetonitrile or DMF as solvent. In acetonitrile at 80 or 150 °C for 30 min, [^{18}F]**8** was obtained in 19% RCY, respectively. RCYs were similar in DMF under the same conditions. Thus, the 2-bromo-1,3-thiazoles **1** and **2** show reactivity towards radiofluorination that is similar to that of 2-bromopyridine.²¹

The effect of halo leaving group on radiofluorination yield was examined with the 2-halo-thiazole precursors **3–5**. In one set of experiments, using a single batch of dry [^{18}F]F⁻-K⁺-K 2.2.2 under identical reaction conditions (DMSO, 130 °C, 8 min, MW), [^{18}F]**9** was obtained from **3**, **4** and **5** in 14.5%, 14% and 2.0% RCY, respectively. This shows that chloro and bromo are the preferred halo leaving groups, as for halo-benzenes.⁶

The production of [^{18}F]**9** from bromo precursor **4** was performed in DMSO under argon with microwave heating at 130 °C for 10 min and an improved 45% RCY was obtained. Similarly, the bromo precursor **6** was radiofluorinated under microwave condition to give [^{18}F]**10** in 23% RCY. Conditions for this later reaction were not optimized.

In conclusion, we developed a mild and operationally simple procedure for preparing 2-fluoro-1,3-thiazoles in high yield by nucleophilic substitution with fluoride ion from readily prepared halo precursors under microwave irradiation. This procedure was successfully adapted to the rapid labeling of potential new radioligands with NCA [^{18}F]fluoride ion under thermal or microwave heating conditions for potential application in PET imaging. The generated 2-fluoro compounds are expected to show desirably high resistance to defluorination in vivo. Thus 2-fluoro-1,3-thiazolyl and [^{18}F]2-fluorothiazolyl moieties may now prove to be usefully new structural motifs for drugs and radioligands, respectively.

Acknowledgment

This work was supported by the Intramural Research Program of the National Institutes of Health (NIMH).

Supplementary data

Supplementary data (experimental procedures, characterization data for new compounds **9–10**, and representative radio-HPLC chromatograms for compounds [^{18}F]**7**–[^{18}F]**10**) associated with

this article can be found in the online version, at doi:10.1016/j.tetlet.2010.09.037.

References and notes

- Hagmann, W. K. *J. Med. Chem.* **2008**, *51*, 4359–4369.
- Müller, K.; Faeh, C.; Diederich, F. *Science* **2007**, *317*, 1881–1886.
- Phelps, M. E. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 9226–9233.
- (a) Watson, D. A.; Su, M.; Teverovskiy, G.; Zhang, Y.; García, F. J.; Kinzel, T.; Buchwald, S. L. *Science* **2009**, *325*, 1661–1664; (b) Furuya, T.; Kaiser, H. M.; Ritter, T. *Angew. Chem., Int. Ed.* **2008**, *47*, 5993–5996.
- (a) Ruth, T. J.; Wolf, A. P. *Radiochim. Acta* **1979**, *26*, 21–24; (b) Guillaume, M.; Luxen, A.; Nebeling, B.; Argentinini, M.; Clark, J. C.; Pike, V. W. *Appl. Radiat. Isot.* **1991**, *42*, 749–762.
- Cai, L.; Lu, S.; Pike, V. W. *Eur. J. Org. Chem.* **2008**, *17*, 2853–2873.
- Pike, V. W. *Trends Pharmacol. Sci.* **2009**, *30*, 431–440.
- (a) Dolci, L.; Dollé, F.; Jubeau, S.; Vaufray, F.; Crouzel, C. *J. Labelled Compd. Radiopharm.* **1999**, *42*, 975–985; (b) Dollé, F. In *PET Chemistry—The Driving Force in Molecular Imaging*, Schubiger, P. A.; Lehman, L.; Friebe, M., Eds., Springer, 2007; Chapter 5, pp 114–157.
- (a) Pike, V. W.; Aigbirhio, F. I. *J. Chem. Soc., Chem. Commun.* **1995**, 2215–2216; (b) Shah, A.; Pike, V. W.; Widdowson, D. A. *J. Chem. Soc., Perkin Trans. 1* **1998**, 2043–2046; (c) Ross, T. L.; Ermert, J.; Hocke, C.; Coenen, H. H. *J. Am. Chem. Soc.* **2007**, *129*, 8018–8025; (d) Carroll, M. A.; Nairne, J.; Woodcraft, J. L. *J. Labelled Compd. Radiopharm.* **2007**, *50*, 452–454; (e) Chun, J.-H.; Lu, S.; Lee, Y.-S.; Pike, V. W. *J. Org. Chem.* **2010**, *75*, 3332–3338.
- The Practice of Medicinal Chemistry*; Wermuth, C. G., Ed., 2nd ed.; Academic Press, 2003.
- (a) Slassi, A.; Isaac, M.; Edwards, L.; Minindis, A.; Wensbo, D.; Mattson, J.; Nilsson, K.; Raboison, P.; McLeod, D.; Stormann, T. M.; Hammerland, L. G.; Johnson, E. *Curr. Top. Med. Chem.* **2005**, *5*, 897–911; (b) Siméon, F. G.; Brown, A. K.; Zoghbi, S. S.; Patterson, V. M.; Innis, R. B.; Pike, V. W. *J. Med. Chem.* **2007**, *50*, 3256–3266.
- Yang, X.; Chen, W. *Xenobiotica* **2005**, *35*, 797–809.
- Briner, P. H.; Fyfe, M. C. T.; Martin, P.; Murray, P. J.; Naud, F.; Procter, M. J. *Org. Process Res. Dev.* **2006**, *10*, 346–348.
- (a) Grünert, C.; Wiechert, K. *Zeitsch. Chem.* **1970**, *10*, 188–189; (b) Lowe, G.; Potter, B. V. L. *J. Chem. Soc., Perkin Trans. 1* **1980**, 2026–2028; (c) Kim, Y. H.; Lee, C. H.; Ki, Y. C. *Tetrahedron Lett.* **1990**, *31*, 3019–3022; (d) Yoneda, N.; Fukuhara, T. *Tetrahedron* **1996**, *52*, 23–26; (e) Berger, R.; Chang, L.; Edmondson, S. D.; Globe, S. D.; Ha, S. N.; Kar, N. F.; Kopka, I. E.; Li, B.; Morriello, G. J.; Moyes, C. R.; Shen, D.-M.; Wang, L.; Zhu, C. U.S. Patent 253705 A1, 2009.
- Bartoli, G.; Latrofa, A.; Naso, F.; Todesco, P. E. *J. Chem. Soc., Perkin Trans. 1* **1972**, 2671.
- (a) Gallagher, P. T.; Iddon, B.; Suschitzky, H. *J. Chem. Soc., Perkin Trans. 1* **1980**, 2358–2361; (b) Beck, G.; Schubert, R. U.S. Patent 4,788,208, 1988.; (c) Benoit, M.; Demoute, J.-P.; Wehrey, C. Eur. Patent 0556123 A1, 1993.; (d) Kim, Y.-H. *Phosphorus, Sulfur Silicon Relat. Elem.* **1993**, *74*, 249–260.
- Siméon, F. G.; Wendahl, M. T.; Pike, V. W. *J. Org. Chem.* **2009**, *74*, 2578–2581.
- Cosford, N. D. P.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodtkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M. A. *J. Med. Chem.* **2003**, *46*, 204–206.
- (a) Guzcoghly, L.; Puklics, M.; Toth, G.; Szabo, G.; Palfi, D. Fr. Patent 72-30738, 1973.; (b) Tashika, Y.; Ito, T.; Takanashi, K.; Ono, M. Jpn. Tokkyo Koho JP 19650309, 1967.
- Schiffmann, R.; Neugebauer, A.; Klein, C. D. *J. Med. Chem.* **2006**, *49*, 511–522.
- (a) Greguric, I.; Taylor, S. R.; Denoyer, D.; Ballantyne, P.; Berghofer, P.; Roselt, P.; Pham, T. Q.; Mattner, F.; Bourdier, T.; Neels, O. C.; Dorow, D. S.; Loch, C.; Hicks, R. J.; Katsifis, A. *J. Med. Chem.* **2009**, *52*, 5299–5302; (b) Dolci, L.; Valette, H.; Vaufray, F.; Fuseau, C.; Bottlaender, M.; Crouzel, C. *Bioorg. Med. Chem.* **1999**, *7*, 467–479.